Skin Cancer | Topics

Pembrolizumab Induces Robust, Durable Antitumor Activity in Advanced CSCC
April 11, 2021

These data establish pembrolizumab as a promising treatment option for those with locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma, according to Brett G.M. Hughes, MD.

First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal Melanoma
February 11, 2021

First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.

FDA Approves Cemiplimab as First Immunotherapy to Treat Patients With Advanced BCC
February 09, 2021

The PD-1 inhibitor cemiplimab was granted approval in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom these therapies are not appropriate.

Looking at MCC Diagnoses Over Time Reveal Varying Effects Account for Incidence Rates
January 11, 2021

A study published in JAMA Dermatology found changes in diagnostics and awareness may, in part, account for initial increases in incidence rates for Merkel cell carcinoma.

Study Finds Incidence Rates of cSCC Continue to Increase, Especially Among Females
November 16, 2020

Study investigators indicated that these results call for the need to revise skin cancer health policies to be able to handle the increasing burden of keratinocyte carcinoma management.

Topical Immunosuppressants Drugs Don’t Increase Risk of Common Skin Cancers, Despite Warning Labels
October 05, 2020

A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.

PD-1 antibody Induces Clinical Activity in Patients with Locally Advanced Basal Cell Carcinoma
September 18, 2020

Cemiplimab demonstrated an objective response rate of 31% in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors.

Personalized Cancer Vaccine Shows Long-Term Survival for Patients with High-Risk Melanoma
August 06, 2020

Data released from a phase 2b clinical trial showed statistically significant long-term survival for patients with stage III or IV melanoma at high-risk of recurrence.

FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma
June 24, 2020

The FDA approved pembrolizumab for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

Increases in Melanoma Risk in Patients Treated with Biologic Therapy Not Ruled Out
May 25, 2020

Clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot yet be ruled out based on current evidence.